腎デナベーション市場 - 世界の産業規模、シェア、動向、機会、予測：技術別、製品別、治療領域別、エンドユーザー別、地域別、競合別、2020年～2030年

腎デナベーションの世界市場規模は2024年に5億1,234万米ドルで、予測期間中のCAGRは9.45%で2030年には8億7,385万米ドルに達すると予測されています。

腎デナベーションの世界市場は、高血圧の有病率の増加と、耐性症例の管理における薬理療法の限界によって、大きな成長を遂げています。腎デナベーションは、腎動脈の過剰な交感神経を標的とすることで新たなアプローチを提供し、従来の薬物療法で十分な効果が得られない患者に代替治療を提供します。高齢化社会の進展、非薬物療法の選択肢に対する意識の高まり、安全性と有効性を高めるカテーテルベースの技術の進歩などが需要を支えています。高周波、超音波、化学物質をベースとしたアブレーション法の革新により治療範囲が拡大し、医療従事者や血圧がコントロールできない状態に対する長期的な解決策を求める患者にとって、この治療法はより魅力的なものとなっています。市場拡大には、降圧剤を服用していない患者を含むさまざまな患者グループにおいて、腎デナベーションによる血圧低下の効果を検証する臨床試験が増加していることも影響しています。病院、専門クリニック、外来手術センターでは、心血管治療のプロトコールにこの治療法を取り入れるケースが増えています。規制当局の承認が普及し、医療制度が慢性高血圧の経済的負担の軽減を目指す中、腎デナベーションは世界的に一層の普及が見込まれています。研究開発への投資が増加し、医師の間で認知度が高まっていることから、同市場は着実な成長を遂げるものと思われます。

市場促進要因

高血圧の有病率の上昇

主な市場課題

長期臨床データの不足

主要市場動向

超音波とマイクロインフュージョンを支持する技術の進化

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の腎デナベーション市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（超音波アブレーション、高周波アブレーション、薬理学的アブレーション、マイクロインフュージョン）
  • 製品別（カテーテル、単電極カテーテル、多電極カテーテル、RFジェネレータ、その他）
  • 治療領域別（高血圧、心不全、糖尿病、腎不全、その他）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 技術別
  • 製品別
  • 治癒領域別
  • エンドユーザー別
  • 地域別

第6章 北米の腎デナベーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の腎デナベーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の腎デナベーション市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の腎デナベーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの腎デナベーション市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 競合情勢

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc.（Otsuka Holdings）
• Cardiosonic Ltd
• Mercator MedSystems, Inc
• Renal Dynamics Limited

第14章 戦略的提言

第15章 調査会社について・免責事項

Global Renal Denervation Market was valued at USD 512.34 Million in 2024 and is expected to reach USD 873.85 Million by 2030 with a CAGR of 9.45% during the forecast period. The global renal denervation market is witnessing significant growth driven by the increasing prevalence of hypertension and the limitations of pharmacological therapies in managing resistant cases. Renal denervation offers a novel approach by targeting the overactive sympathetic nerves in the renal arteries, providing an alternative treatment for patients who fail to respond adequately to conventional medications. The demand is supported by a growing aging population, rising awareness of non-pharmacologic treatment options, and advancements in catheter-based technologies that enhance procedural safety and efficacy. Innovation in radiofrequency, ultrasound, and chemical-based ablation methods has expanded the scope of treatment, making the procedure more appealing to healthcare providers and patients seeking long-term solutions to uncontrolled blood pressure. Market expansion is also influenced by the growing number of clinical trials validating the benefits of renal denervation in reducing blood pressure across various patient groups, including those not on antihypertensive drugs. Hospitals, specialty clinics, and ambulatory surgical centers are increasingly incorporating this therapy into their cardiovascular care protocols. As regulatory approvals become more widespread and healthcare systems seek to reduce the economic burden of chronic hypertension, renal denervation is expected to gain more traction globally. The market is positioned for steady growth with increasing investments in R&D and expanding awareness among physicians.

Key Market Drivers

Rising Prevalence of Hypertension

The rising prevalence of hypertension is a key factor influencing the growth of the global renal denervation market. Hypertension has become one of the most common chronic health conditions worldwide, driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, obesity, and increased stress levels. For instance, according to WHO 2023, about 1.28 billion adults aged 30-79 suffer from hypertension globally, with two-thirds living in low- and middle-income countries. Nearly 46% are unaware of their condition, only 42% receive treatment, and just 21% have it under control. Reducing hypertension prevalence by 33% by 2030 remains a global health target. As the number of individuals diagnosed with high blood pressure continues to climb, so does the demand for more effective and sustainable treatment options. A significant proportion of patients experience resistant hypertension, where blood pressure remains high despite the use of three or more antihypertensive medications. This segment presents a major challenge in clinical practice and highlights the need for alternative solutions beyond drug therapy. Renal denervation has emerged as a promising intervention in such cases, offering a minimally invasive, device-based treatment that directly targets the overactive renal sympathetic nerves. For instance, according to the CDC, in 2022, high blood pressure was a primary or contributing factor in 685,875 deaths in the U.S. Around one in five COVID-19-related deaths occurred in individuals with a history of hypertensive disease, highlighting its significant role in overall mortality. The growing population of patients with uncontrolled or drug-intolerant hypertension makes renal denervation an attractive option for healthcare providers seeking to improve long-term outcomes. As awareness grows about the limitations of current pharmacological approaches, interest in non-pharmacologic interventions is rising. This trend is positioning renal denervation as an increasingly important tool in the global effort to manage hypertension more effectively and reduce its associated health risks.

Key Market Challenges

Lack of long-term clinical data

The lack of long-term clinical data remains one of the most significant challenges impacting the growth and acceptance of the global renal denervation market. While recent clinical trials have shown encouraging short-term results in reducing blood pressure among patients with resistant hypertension, healthcare providers and regulatory bodies still seek more comprehensive, long-term evidence to support widespread clinical adoption. Decision-makers in healthcare systems are cautious about incorporating device-based interventions without robust data that demonstrate sustained efficacy and safety over extended periods. Short-term reductions in blood pressure are promising, but the true value of renal denervation lies in its ability to maintain control over time and reduce the risk of major cardiovascular events. Without long-term follow-up data, it is difficult to evaluate whether the initial benefits translate into lasting improvements in patient outcomes, such as reduced incidence of stroke, heart attack, or kidney failure. The absence of extended trial data also creates uncertainty around patient selection, optimal procedural techniques, and the durability of nerve ablation. This uncertainty can hinder physician confidence, delay reimbursement decisions, and discourage investment in technology. Payers are particularly reluctant to fund procedures that lack evidence of cost-effectiveness over time, especially when compared to well-established pharmaceutical therapies. For renal denervation to gain broader acceptance as a routine clinical option, it must demonstrate long-term superiority or complementarity to drug therapy in managing resistant hypertension. Until large-scale, long-duration studies are completed and peer-reviewed, many stakeholders will remain hesitant. Ongoing research and continued post-market surveillance will play a critical role in addressing these concerns, but the current lack of longitudinal evidence remains a barrier to faster adoption. This gap in data not only affects market growth but also influences clinical guidelines and patient access to this potentially transformative therapy.

Key Market Trends

Technology evolution favoring ultrasound and micro-infusion

Technological evolution is playing a central role in the transformation of the global renal denervation market, with a growing shift toward ultrasound and micro-infusion-based systems. While radiofrequency ablation has historically been the standard approach, ultrasound technology is gaining momentum due to its ability to deliver circumferential energy around the arterial wall without requiring direct contact. This feature allows for more uniform nerve ablation and reduces the risk of procedural complications, making it an increasingly attractive option for physicians. The use of ultrasound catheters enables consistent and efficient denervation with shorter procedure times and improved safety profiles. These benefits are particularly important in clinical settings focused on precision and outcomes. Micro-infusion techniques, which involve delivering chemical agents directly into the perivascular space, are also emerging as a promising alternative. This method targets nerve endings with high specificity, allowing for controlled and localized ablation while minimizing damage to surrounding tissues. As companies invest in refining these systems, micro-infusion offers potential advantages for patients who may not be ideal candidates for thermal ablation. The advancement of these technologies is reshaping the competitive landscape, encouraging the development of next-generation devices that combine imaging guidance, real-time feedback, and customizable ablation protocols. With ongoing clinical trials and regulatory interest, ultrasound and micro-infusion platforms are driving innovation and expanding the range of renal denervation options available to physicians. These technologies align with the broader trend in medicine toward less invasive, more targeted interventions that prioritize both efficacy and patient safety. As adoption increases, they are expected to play a key role in elevating the clinical standards for treating resistant hypertension. The transition toward these newer methods reflects a market focused on improving procedural consistency, expanding treatment access, and enhancing long-term outcomes through continuous technological progress.

Key Market Players

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc. (Otsuka Holdings)
• Cardiosonic Ltd.
• Mercator MedSystems, Inc.
• Renal Dynamics Limited

Report Scope:

In this report, the Global Renal Denervation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Denervation Market, By Technology:

• Ultrasound Ablation
• Radiofrequency Ablation
• Pharmacologic Ablation
• Microinfusion

Renal Denervation Market, By Product:

• Catheters
• Single Electrode Catheter
• Multi Electrode Catheter
• RF Generator
• Others

Renal Denervation Market, By Therapeutic Area:

• Hypertension
• Heart Failure
• Diabetes
• Renal Failure
• Others

Renal Denervation Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Renal Denervation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Denervation Market.

Available Customizations:

Global Renal Denervation Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Denervation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)
  • 5.2.2. By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)
  • 5.2.3. By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Product
  • 5.3.3. By Therapeutic Area
  • 5.3.4. By End User
  • 5.3.5. By Region

6. North America Renal Denervation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Renal Denervation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Renal Denervation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Renal Denervation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User

7. Europe Renal Denervation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Renal Denervation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Renal Denervation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Renal Denervation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Renal Denervation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Therapeutic Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Renal Denervation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Therapeutic Area
      • 7.3.5.2.4. By End User

8. Asia-Pacific Renal Denervation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Renal Denervation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Renal Denervation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Renal Denervation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Renal Denervation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Therapeutic Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Renal Denervation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Therapeutic Area
      • 8.3.5.2.4. By End User

9. South America Renal Denervation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Renal Denervation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Renal Denervation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Renal Denervation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Middle East and Africa Renal Denervation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Renal Denervation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Therapeutic Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Renal Denervation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Therapeutic Area
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Renal Denervation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Therapeutic Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Medtronic Plc.
  • 13.1.1. Business Overview
  • 13.1.2. Company Snapshot
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Recent Developments
  • 13.1.6. SWOT Analysis
• 13.2. Boston Scientific Corporation
• 13.3. Abbott Laboratories, Inc.
• 13.4. Terumo Corporation
• 13.5. Johnson & Johnson
• 13.6. Cordis Corporation
• 13.7. ReCor Medical, Inc. (Otsuka Holdings)
• 13.8. Cardiosonic Ltd
• 13.9. Mercator MedSystems, Inc
• 13.10. Renal Dynamics Limited

14. Strategic Recommendations

15. About Us & Disclaimer